Tower Health Hematology and Medical Oncology

Topics

• Chemotherapy-induced cardiotoxicity and mitigation 50
• Cancer survivorship and care 33
• COVID-19 and healthcare impacts 12
• Vascular Malformations and Hemangiomas 12
• Economic and Financial Impacts of Cancer 11
• Childhood Cancer Survivors' Quality of Life 9
• Lymphoma Diagnosis and Treatment 9
• Cancer Immunotherapy and Biomarkers 8
• Viral-associated cancers and disorders 8
• Breast Cancer Treatment Studies 7
• Platelet Disorders and Treatments 7
• BRCA gene mutations in cancer 6

Most cited

1. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.

   European heart journal · 2022 · 517 citations · Anne Blaes

2. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.

   The New England journal of medicine · 2023 · 303 citations · Shelley Crary

3. Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America.

   Journal of cardiac failure · 2025 · 74 citations · Anne Blaes

4. The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review.

   JACC. CardioOncology · 2024 · 102 citations · Anne Blaes

5. Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations.

   JACC. CardioOncology · 2025 · 52 citations · Anne Blaes

6. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC).

   NPJ breast cancer · 2025 · 49 citations · Anne Blaes